This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HAE vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Is Butterfly Network (BFLY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Butterfly Network, Inc. (BFLY) and Haemonetics (HAE) have performed compared to their sector so far this year.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are upbeat about Haemonetics (HAE) owing to impressive Plasma and Hospital business performance, with continued strength in the Hemostasis Management product line.
4 Low-Beta Stocks to Buy to Endure Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Haemonetics (HAE), The Kroger Co. (KR), JOYY (YY) and Novo Nordisk (NVO) are poised to gain.
AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.
Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays
by Zacks Equity Research
Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.
Thermo Fisher (TMO) Partners With ArsenalBio for Cancer R&D
by Zacks Equity Research
Thermo Fisher's (TMO) latest collaboration with ArsenalBio supports the latter's clinical manufacturing of autologous T-cell therapies for advanced cancer treatment.
Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch
by Zacks Equity Research
Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.
Insulet (PODD) Benefits From Omnipod 5 Launch, Expansion
by Zacks Equity Research
Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.
Thermo Fisher (TMO) Opens New Cell Therapy Facility at UCSF
by Zacks Equity Research
Thermo Fisher's (TMO) new cell therapy facility at UCSF is likely to accelerate the development of advanced therapies.
Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales decline reflects lower demand for COVID-19 services.
Abbott's (ABT) CardioMEMS Favors Heart Failure Management
by Zacks Equity Research
Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patients.
HAE vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs
by Zacks Equity Research
The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.
Smith & Nephew's (SNN) CIT Technology Favored by New Study
by Zacks Equity Research
Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.
Syneos Health (SYNH) Partners With KX for Data-Driven Insights
by Zacks Equity Research
Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.
Henry Schein (HSIC) Bolsters Dental Practices With AI Tools
by Zacks Equity Research
Henry Schein (HSIC) integrates AI-enabled solutions, Dentrix Ascend Detect AI and Dentrix Ascend Voice, into its cloud-based dental software.
Quest Diagnostics (DGX) Acquires Northern Light Laboratory
by Zacks Equity Research
Quest Diagnostics (DGX) now offers professional laboratory management services for nine of Northern Light Health's hospital laboratories.
NuVasive's (NUVA) Precice System Cleared for Pediatric Patients
by Zacks Equity Research
NuVasive (NUVA) receives FDA 510(k) clearance for using the Precice limb lengthening system for treating pediatric patients.
Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes
by Zacks Equity Research
Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).
Quest Diagnostics (DGX) Updates Its Strategic Focus, LT Growth
by Zacks Equity Research
Quest Diagnostics (DGX) is building strong platforms to focus on high-growth areas like molecular genomics and oncology.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX), led by impressive value-added acquisitions.
Bruker (BRKR) Receives 1.2 GHz NMR System Orders From the UK
by Zacks Equity Research
Bruker (BRKR) extends support to the expansion efforts of the UK Science community by providing 1.2 GHz Avance NMR spectrometers.
Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2
by Zacks Equity Research
Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.